Evidence map›Paper›PMID 30218485›Full record

ArticleInfluenza and other respiratory viruses2019

Replacement of neuraminidase inhibitor-susceptible influenza A(H1N1) with resistant phenotype in 2008 and circulation of susceptible influenza A and B viruses during 2009-2013, South Africa.

Florette K Treurnicht, Amelia Buys, Stefano Tempia, Mpho Seleka, Adam L Cohen, Sibongile Walaza, Allison J Glass, Inéz Rossouw, Johanna McAnerney, Lucille Blumberg and 2 more

Open access · goldAbstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Molecular Evolution of Influenza A Viruses From Mauritius, 2017-2019.Influenza and other respiratory viruses · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Florette K TreurnichtCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0002-0853-8011
Amelia BuysCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Stefano TempiaInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID 0000-0003-4395-347X
Mpho SelekaCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Adam L CohenInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Sibongile WalazaCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Allison J GlassDepartment of Molecular Pathology, Lancet Laboratories, Johannesburg, South Africa.
Inéz RossouwPathCare Laboratories, PathCare Park, Cape Town, South Africa.
Johanna McAnerneyCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Lucille BlumbergFaculty of Health Sciences, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
Cheryl CohenCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
Marietjie VenterDepartment of Medical Virology, Emerging Arbo-and Respiratory Virus Program, University of Pretoria, Pretoria, South Africa.
National Health Laboratory Service · ZACenters for Disease Control and Prevention · USLancet Laboratories · ZA

Funding

Research on the Epidemiology,Prevention,Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in South Africa.09U01IP001048 · IP · NATIONAL HEALTH LABORATORY SERVICE · PI COHEN, CHERYL · 2016 to 2020
$19.9M
CDC HHS 1U51IP000528NCIRD CDC HHS U01 IP001048World Health Organization 001
6 · The paper itself

Abstract

backgroundData on the susceptibility of influenza viruses from South Africa to neuraminidase inhibitors (NAIs) are scarce, and no extensive analysis was done.

objectivesWe aimed to determine oseltamivir and zanamivir susceptibility of influenza A and B virus neuraminidases (NAs), 2007-2013, South Africa. PATIENTS/

methodsWe enrolled participants through national influenza-like illness surveillance, 2007-2013. Influenza diagnosis was by virus isolation and quantitative polymerase chain reaction (qPCR). Drug susceptibility was determined by chemiluminescence-based NA-STAR/NA-XTD assay. Sanger sequencing was used to determine molecular markers of NAI resistance.

resultsForty percent (6341/15 985) of participants were positive for influenza viruses using virus isolation (2007-2009) and qPCR (2009-2013) methods. A total of 1236/6341 (19.5%) virus isolates were generated of which 307/1236 (25%) were tested for drug susceptibility. During 2007-2008, the median 50% inhibitory concentration (IC

conclusionsWe confirm replacement of NAI susceptible by resistant phenotype influenza A(H1N1) in 2008. Influenza A and B viruses (2009-2013) remained susceptible to NAIs; therefore, these drugs are useful for treating influenza-infected patients.

Indexed as

Amino Acid SubstitutionDrug Resistance, ViralEnzyme InhibitorsHumansInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza B virusInfluenza, HumanInhibitory Concentration 50NeuraminidaseOseltamivirPhenotypeSeasonsSentinel SurveillanceSouth AfricaViral ProteinsEnzyme InhibitorsNA protein, influenza A virusNeuraminidaseOseltamivirViral ProteinsZanamivirinfluenzaoseltamivirSouth Africasusceptibility

Identifiers

PMID30218485
PMCPMC6304311
OpenAlexW2891122769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.